Clinical trials: Pulmonary Tuberculoses
Pulmonary Disease, Pulmonary Infection
A Prospective Registry For Patients With Non-Tuberculous Mycobacterial (NTM) Pulmonary Disease in Korea.
The incidence and prevalence of pulmonary disease due to Non-tuberculous mycobacteria (NTM) is increasing worldwide, and this trend has been confirmed in Korea.
- Conditions
- Pulmonary Disease, Pulmonary Infection, Non-Tuberculous Mycobacterial Pneumonia
- Trial name
- NTM-KOREA (NCT03934034)
- Volunteers
- 1,000 people
- Sponsor
- Seoul National University Hospital
Tuberculosis, Tuberculosis, Pulmonary
Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers
The aim of this study is to evaluate (1) the safety and tolerability of escalating doses of rifapentine (RPT) administered daily by oral; (2) the effect of increasing doses of RPT on cytochrome P450 isoform 3A (CYP3A) enzyme…
- Trial name
- TBTC S29B (NCT01162486)
- Testing
- Rifampin & midazolam, rifapentine & midazolam, rifapentine and midazolam
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Tuberculosis, Pulmonary, Antibiotic Prophylaxis
Prevention of Tuberculosis in Prisons
The purpose of this study is to determine if the isoniazid is effective in the prevention of tuberculosis in a prison population, exposed to the high endemicity of the disease.
- Trial name
- NCT03028129
- Testing
- Isoniazid 900 milligrams
- Where
- Brazil
- Volunteers
- 467 people, healthy volunteers welcome
- Sponsor
- Federal University of Mato Grosso
Pulmonary Tuberculosis
Pharmacokinetic Study of Patients Who Undergo Cycloserine, a 2nd-line Antituberculosis Medicament
In all treatments of tuberculosis, the second-line drugs are usually less effective but have more drug toxicity than the first-line ones.
- Trial name
- CSPK (NCT01002170)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Taipei Medical University WanFang Hospital
Pulmonary Tuberculosis
Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT)
The purpose of this study is to elucidate whether the individualized medicine based on NAT2 gene polymorphism could improve the safety, efficacy and economical benefits of multi-drug therapy for the pulmonary tuberculosis with…
- Trial name
- NCT00298870
- Testing
- Isoniazid, isoniazed
- Where
- 4 sites in Japan
- Volunteers
- 172 people
- Sponsor
- Osaka University
Tuberculosis, Pulmonary
Evaluation of CRISPR-based Test for the Rapid Identification of TB in Pulmonary Tuberculosis Suspects
This observational Mycobacterium tuberculosis (MTB) diagnostics evaluation study is a prospective study of pulmonary TB suspects who are undergoing sputum or bronchoalveolar lavage fluid (BALF) evaluation for pulmonary TB.
- Trial name
- NCT04074369
- Testing
- CRISPR-based Test
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Huashan Hospital
Mediastinal Lymphadenopathy, Lung Cancer
Mediastinal EBUS Cryobiopsy Study In Sweden
This study is a prospective observational non-randomized clinical trial where all the participitants undergo the same procedure and every participitant's samples are compared to each other.
- Conditions
- Mediastinal Lymphadenopathy, Lung Cancer, Sarcoidosis, Lymphoma
- Trial name
- MECRIS (NCT06347939)
- Testing
- Mediastinal lymph nodes cryobiopsies
- Where
- 2 sites in Sweden
- Volunteers
- 200 people
- Sponsor
- Region Skane
Tuberculosis, Pulmonary
Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis
This study is proposed to evaluate the safety and efficacy of the RUTI vaccine in patients with pulmonary tuberculosis. Therapeutic vaccination of RUTI would stimulate the immune response not only against growing bacteria, but…
- Trial name
- CONSTAN-ARG (NCT05455112)
- Testing
- RUTI® Vaccine
- Where
- 2 sites in Argentina
- Volunteers
- 41 people
- Sponsor
- Archivel Farma S.L.
Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection
Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
The goal of this clinical trial is to learn if a new combination antibiotic treatment (Arm D) works to treat a rare lung condition called mycobacterium abscessus pulmonary disease in people of any age and sex, when compared to…
- Conditions
- Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections, Non-Tuberculous Mycobacteria Pulmonary Disease
- Trial name
- FORMaT-EVOLVE (NCT07485010)
- Testing
- Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin
- Volunteers
- 300 people
- Sponsor
- The University of Queensland
Non-Tuberculous Mycobacterial Pneumonia
Cellular Markers in Treated or Untreated Non-tuberculous Mycobacterial Respiratory Infection in Patients With Cystic Fibrosis
This study evaluates a diagnostic serological test for Non-Tuberculous Mycobacteria (NTM) infection in cystic fibrosis patients by measuring T cell response.
- Trial name
- MUCEM (NCT06602869)
- Testing
- Scheduled visit (V1)
- Where
- France
- Volunteers
- 76 people
- Sponsor
- University Hospital, Montpellier
Tuberculosis, Pulmonary
Pharmacokinetics of Ethionamide and Ethionamide Sulfoxide in Patients Established on Treatment for Tuberculosis.
To determine the pharmacokinetics of ethionamide (Eto) and ethionamide-sulfoxide (Eto-SO) in participants with tuberculosis (TB) when Eto is dosed under programmatic conditions.
- Trial name
- NCT05258877
- Testing
- Plasma samples
- Where
- South Africa
- Volunteers
- 30 people
- Sponsor
- BioVersys AG
Pulmonary Tuberculosis
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)
The trial will evaluate the extended bactericidal activity of 14 consecutive days of oral administration of TMC207 alone, TMC207 with pyrazinamide, TMC207 with PA-824, PA-824 with pyrazinamide and PA-824 with moxifloxacin and…
- Trial name
- NCT01215851
- Testing
- PA-824, Pyrazinamide, TMC207
- Where
- 2 sites in South Africa
- Volunteers
- 85 people
- Sponsor
- Global Alliance for TB Drug Development
COVID-19, Tuberculosis
Tuberculosis as a Risk Factor for a Worse Outcome Post-Sars-CoV-2 Infection
This study has two main objectives. First, the clinical characteristics and outcomes of hospitalized patients with symptomatic Covid-19 disease will be compared between persons with a history of past or current TB infection or…
- Conditions
- COVID-19, Tuberculosis, Post-acute COVID-19 Syndrome
- Trial name
- Co-TB (NCT05643781)
- Where
- South Africa
- Volunteers
- 157 people
- Sponsor
- The Aurum Institute NPC
Tuberculosis, Multidrug-Resistant, Infection, Bacterial
Evaluating Newly Approved Drugs for Multidrug-resistant TB
endTB Clinical Trial a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of five new, all-oral, shortened regimens for multidrug-resistant tuberculosis (MDR-TB).
- Conditions
- Tuberculosis, Multidrug-Resistant, Infection, Bacterial, Pulmonary Tuberculoses
- Trial name
- endTB (NCT02754765)
- Testing
- Bedaquiline, Delamanid, Clofazimine
- Where
- 12 sites in Georgia, India and 5 more
- Volunteers
- 754 people
- Sponsor
- Médecins Sans Frontières, France
Tuberculosis
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)
The A5414 study will evaluate whether treatment for drug-susceptible pulmonary tuberculosis (TB) can be tailored according to a participant's risk of an unfavorable outcome.
- Trial name
- NCT07595042
- Testing
- Isoniazid, Rifampin, Pyrazinamide
- Where
- 29 sites in Argentina, Australia and 14 more
- Volunteers
- 900 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumonia, Tuberculosis, Pulmonary
The LalelaLung Study: Digital Stethoscope Clinical Evaluation
Pneumonia is the leading infectious cause of death in children under five years of age worldwide, and most of these deaths occur in low- and middle-income countries.
- Conditions
- Pneumonia, Tuberculosis, Pulmonary, Respiratory Tract Infections, Bronchiolitis
- Trial name
- LaLeLa (NCT07631377)
- Testing
- StethoMe AI-enabled digital stethoscope system, Standard IMCI assessment
- Volunteers
- 350 people
- Sponsor
- Johns Hopkins University
Pulmonary Neoplasm, Pulmonary Tuberculosis
Could the Stroke Volume Variation Predict a Fluid Responsiveness in Thoracotomy?
There are some risks of pulmonary edema in patients undergoing pulmonary lobectomy with one lung ventilation. The overloading of fluid administration could be related to the development of pulmonary edema in patents after…
- Trial name
- NCT02331056
- Testing
- fluid loading, thoracoscopic pulmonary lobectomy, thoracotomy
- Where
- South Korea
- Volunteers
- 79 people
- Sponsor
- Samsung Medical Center
Bronchiectasis Post-Tuberculosis Lung Disease
Respiratory Muscle Stretching for Improving Chest Expansion and Dyspnea in Post-Tuberculosis Bronchiectasis
This study intends to examine the effectiveness of adding RMS to a traditional program of pulmonary rehabilitation regarding chest expansion, dyspnea, and cough symptoms in bronchiectasis post-tuberculosis patients.
- Trial name
- NCT06597409
- Testing
- Standard PR, Standard PR plus Respiratory Muscle Stretching (RMS)
- Where
- Indonesia
- Volunteers
- 48 people
- Sponsor
- Universitas Padjadjaran
Pneumonia, HIV/AIDS
Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia
This trial will evaluate whether empirical treatment against cytomegalovirus and tuberculosis improves survival of HIV-infected infants with severe pneumonia.
- Conditions
- Pneumonia, HIV/AIDS, Tuberculosis, Cytomegalovirus Infections
- Trial name
- EMPIRICAL (NCT03915366)
- Testing
- Valganciclovir Oral Solution [Valcyte], Tuberculostatic Agents
- Where
- 13 sites in Côte d’Ivoire, France and 9 more
- Volunteers
- 563 people
- Sponsor
- Hospital Universitario 12 de Octubre
HIV Infections, Tuberculosis
Observational Study of Specificity of Mycobacterium Tuberculosis Screening and Diagnostics in HIV-Infected Individuals
An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with projected rates of requirement for ARV therapy extending to more than 10 million in sub-Saharan…
- Trial name
- NCT00865826
- Testing
- Standardized diagnostic evaluation
- Where
- 13 sites in Botswana, Brazil and 5 more
- Volunteers
- 801 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections